Your browser doesn't support javascript.
loading
Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.
Herkert, Barbara; Kauffmann, Audrey; Mollé, Sandra; Schnell, Christian; Ferrat, Thomas; Voshol, Hans; Juengert, Janina; Erasimus, Hélène; Marszalek, Grégory; Kazic-Legueux, Malika; Billy, Eric; Ruddy, David; Stump, Mark; Guthy, Daniel; Ristov, Mitko; Calkins, Keith; Maira, Sauveur-Michel; Sellers, William R; Hofmann, Francesco; Hall, Michael N; Brachmann, Saskia M.
  • Herkert B; Novartis Institutes for Biomedical Research (NIBR), Disease Area Oncology, Basel, Switzerland.
  • Kauffmann A; Novartis Institutes for Biomedical Research (NIBR), Disease Area Oncology, Basel, Switzerland.
  • Mollé S; Novartis Institutes for Biomedical Research (NIBR), Disease Area Oncology, Basel, Switzerland.
  • Schnell C; Novartis Institutes for Biomedical Research (NIBR), Disease Area Oncology, Basel, Switzerland.
  • Ferrat T; Novartis Institutes for Biomedical Research (NIBR), Disease Area Oncology, Basel, Switzerland.
  • Voshol H; NIBR, Analytical Sciences and Imaging, Basel, Switzerland.
  • Juengert J; Novartis Institutes for Biomedical Research (NIBR), Disease Area Oncology, Basel, Switzerland.
  • Erasimus H; Novartis Institutes for Biomedical Research (NIBR), Disease Area Oncology, Basel, Switzerland.
  • Marszalek G; Novartis Institutes for Biomedical Research (NIBR), Disease Area Oncology, Basel, Switzerland.
  • Kazic-Legueux M; Novartis Institutes for Biomedical Research (NIBR), Disease Area Oncology, Basel, Switzerland.
  • Billy E; Novartis Institutes for Biomedical Research (NIBR), Disease Area Oncology, Basel, Switzerland.
  • Ruddy D; Novartis Pharma, OTM Translational Research, Cambridge, Massachusetts.
  • Stump M; NIBR, Disease Area Oncology, Cambridge, Massachusetts.
  • Guthy D; Novartis Institutes for Biomedical Research (NIBR), Disease Area Oncology, Basel, Switzerland.
  • Ristov M; Novartis Institutes for Biomedical Research (NIBR), Disease Area Oncology, Basel, Switzerland.
  • Calkins K; Novartis Institutes for Biomedical Research (NIBR), Disease Area Oncology, Basel, Switzerland.
  • Maira SM; Novartis Institutes for Biomedical Research (NIBR), Disease Area Oncology, Basel, Switzerland.
  • Sellers WR; NIBR, Disease Area Oncology, Cambridge, Massachusetts.
  • Hofmann F; Novartis Institutes for Biomedical Research (NIBR), Disease Area Oncology, Basel, Switzerland.
  • Hall MN; Biozentrum, University of Basel, Basel, Switzerland.
  • Brachmann SM; Novartis Institutes for Biomedical Research (NIBR), Disease Area Oncology, Basel, Switzerland. Saskia.brachmann@novartis.com.
Cancer Res ; 76(2): 390-402, 2016 Jan 15.
Article en En | MEDLINE | ID: mdl-26577700
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Receptor IGF Tipo 1 / Sistema de Señalización de MAP Quinasas / Proteínas Proto-Oncogénicas B-raf / Fosfohidrolasa PTEN / Melanoma Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Año: 2016 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Receptor IGF Tipo 1 / Sistema de Señalización de MAP Quinasas / Proteínas Proto-Oncogénicas B-raf / Fosfohidrolasa PTEN / Melanoma Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Año: 2016 Tipo del documento: Article